Home > Insider Trading > Filing (0000899243-20-003363)

Filing Details

Accession Number:: 0000899243-20-003363
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-02-05 17:58:39
Reporting Period:: 2020-02-03

Accepted Time:: 2020-02-05 17:58:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1701541	Black Diamond Therapeutics Inc.	BDTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619841	M. Rajeev Shah	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-02-03	956,723	$0.00	956,723	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	163,353	$0.00	163,353	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	186,749	$0.00	186,749	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	181,783	$0.00	1,138,506	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	70,770	$0.00	234,123	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	30,526	$0.00	217,275	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	785,658	$19.00	1,924,164	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	77,803	$19.00	311,926	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-02-03	136,539	$19.00	353,814	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-02-03	2,885,295	$0.00	956,723	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-02-03	492,643	$0.00	163,353	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-02-03	563,204	$0.00	186,749	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-02-03	548,224	$0.00	181,783	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-02-03	213,429	$0.00	70,770	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-02-03	92,063	$0.00	30,526	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date.
Shares held by RA Capital Healthcare Fund, L.P. (the "Fund"). RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Mr. Shah is a managing member. Mr. Shah disclaims beneficial ownership of the reported securities held by the Fund except to the extent of his pecuniary interest therein.
Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date.
Shares held by RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Adviser is the investment manager for the Nexus Fund. The general partner of the Adviser is the Adviser GP, of which Mr. Shah is a managing member. Mr. Shah disclaims beneficial ownership of the reported securities held by the Nexus Fund except to the extent of his pecuniary interest therein.
Shares held in an account owned by a separately managed account (the "Account"). The Adviser is the investment manager for the Account. The general partner of the Adviser is the Adviser GP, of which Mr. Shah is a managing member. Mr. Shah has no pecuniary interest in the reported securities held in the Account and therefore disclaims beneficial ownership of those securities.
On February 3, 2020, the Fund purchased 785,658 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On February 3, 2020, the Nexus Fund purchased 77,803 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On February 3, 2020, the Account purchased 136,539 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.